Stem cells are one of the most active research fields at present. Based on the unique characteristics of self-renewal and directional differentiation, stem cells have broad prospects in the clinical treatment of cardiovascular diseases, nervous system diseases, hematological diseases, liver diseases, kidney diseases, diabetes mellitus, osteoarthritis diseases and so on. They are called "omnipotent cells" in the medical field with potential market size reaching 400 billion US dollars.
Stem cells can be divided into three types according to their differentiation ability: totipotential stem cell(TSC), multipotential stem cell (MSC), and monopotent stem cells. According to the source of cells, they can be classified as embryonic stem cells and adult stem cells. At present, adult stem cells are the research hotspot.
The future prospects of stem cell therapy in China in the field of technology are considerable, mainly as follows:
Huge market demand
In recent years, cell therapy has become the most cutting-edge means of cancer treatment, and attracted the attention of the global medical market. Our country also starts from the regulatory policy to explore the direction of industrialization of cell therapy. At the same time, "limited opening of stem cell clinical research" and "cell products according to drug management" regulations indicate that the downstream industry of stem cells is beginning to accelerate.
Stem cell technology is becoming more and more mature and popular
Compared with the mature stem cell industry chain abroad, China's stem cell industry is still in the initial stage of development. Only the upstream preparation and storage industry of stem cells is relatively mature, but the overall storage rate of stem cells in the whole country is still less than 1%, and the regional storage rate is not balanced. Compared with the 10-15% storage rate in developed countries, the gap is large.
At present, China's stem cell industry is mainly concentrated in the upstream of the industrial chain, that is, stem cell storage business. The downstream business includes stem cell technology, product development and stem cell therapy. With the development of basic stem cell research and technological progress, with the support of policy norms, personnel training, investment mechanism and other factors, the stem cell industry will usher in a period of rapid development, and the focus of development will shift from upstream to downstream.
The patients' acceptance of stem cell therapy is gradually increasing.
In recent years, with the continuous development of stem cell therapy technology, patients' acceptance of stem cell therapy is gradually improving. Stem cell-based therapies are believed to bring new hope to severe chronic diseases such as colitis, diabetes, arthritis, cirrhosis of the liver, kidney disease, heart disease, chronic obstructive pulmonary disease, etc. With the development of research, the scope of diseases that stem cells can treat is gradually revealed. It is worth mentioning that the list of diseases that stem cells can treat is increasing.
Stem cell therapy has broad medical prospects
Clinical research on stem cell therapy covers more than 140 diseases. In the global stem cell market, cell therapy accounts for half of the total, and has a further expansion trend. Overall, stem cell technology has broad application prospects, and the proportion of stem cell therapy will be further expanded.
Stem cell therapy is widely used in the field of disease treatment with its advantages of proliferation and differentiation.
The application of stem cell therapy in autoimmune diseases, genetic diseases and bone and cartilage repair occupies a relatively high proportion, accounting for 17%, 16% and 16% respectively, and the total proportion of them is close to 50%.
From the analysis of the number of patents applied for stem cells in various countries, we can see that the United States ranks first in the number of patents applied for in this field. The number of patents applied for by the United States reaches 14530, which is far higher than that of other countries, accounting for 44.84% of the total patents in the world. The United States attaches great importance to the research and development of stem cell technology. And the state-owned US National Institutes of Health (NIH) invests more than $1 billion annually in stem cell research. At the same time, local support forces represented by the California Institute of Regenerative Medicine (CIRM) and the participation of large pharmaceutical companies in the United States have jointly promoted the development of stem cell research and development in the United States.
China has applied for 4535 stem cell patents, ranking second in the world, accounting for 7.93% of the total number of global patents. China has always attached great importance to research and development in the field of stem cells. During the 12th Five-Year Plan period, a major national scientific research plan for stem cell research was established, and during the 13th Five-Year Plan period, the state focused on research. The development plan has set up the "stem cell and transformation research" key projects, further promoting the clinical transformation of stem cells and stem cell therapy related technology research and development.
The data show that in 2017, the market size of the stem cell industry in China will reach 315.5 billion yuan, with a pre-value of 25.2 billion yuan, an increase of 25.2% over the same period of last year. The industry will develop rapidly in the coming years, with a large market demand and broad prospects.
It is undeniable that the market of stem cell therapy in China is expanding. It is expected that in 2018, the market size of stem cell and regenerative medicine-related fields in China will exceed 35 billion yuan, whether it is the admission criteria for clinical research, the outsourcing of stem cell research, or even the machine related to stem cell and regenerative medicine research services. Structures will have a huge market share in this industry chain. Therefore, in the early stage of development, early intervention in the stem cell research industry chain will be able to take the lead in the next round of stem cell industry outbreak.